CRISPR Therapeutics Cash from Financing (TTM) Insights

CRISPR Therapeutics AG (CRSP)

53.32 -2.33 (-4.19%) USD | NASDAQ | Apr 25, 10:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2016. Upgrade now.

Date	Value
December 31, 2023	62.66M
September 30, 2023	26.20M
June 30, 2023	39.76M
March 31, 2023	33.35M
December 31, 2022	38.59M
September 30, 2022	42.41M
June 30, 2022	37.51M
March 31, 2022	35.60M
December 31, 2021	250.94M
September 30, 2021	657.27M
June 30, 2021	1.160B
March 31, 2021	1.241B
December 31, 2020	1.016B
September 30, 2020	908.24M
June 30, 2020	466.24M

Date	Value
March 31, 2020	406.39M
December 31, 2019	430.98M
September 30, 2019	125.00M
June 30, 2019	242.33M
March 31, 2019	216.41M
December 31, 2018	315.93M
September 30, 2018	318.49M
June 30, 2018	130.87M
March 31, 2018	127.84M
December 31, 2017	2.608M
September 30, 2017	93.09M
June 30, 2017	88.01M
March 31, 2017	148.24M
December 31, 2016	183.22M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

26.20M

Minimum

Sep 2023

1.241B

Maximum

Mar 2021

380.03M

Average

242.33M

Median

Jun 2019

Cash from Financing (TTM) Benchmarks